These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1056 related items for PubMed ID: 3262202
1. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Vaux DL, Cory S, Adams JM. Nature; 1988 Sep 29; 335(6189):440-2. PubMed ID: 3262202 [Abstract] [Full Text] [Related]
2. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Strasser A, Harris AW, Bath ML, Cory S. Nature; 1990 Nov 22; 348(6299):331-3. PubMed ID: 2250704 [Abstract] [Full Text] [Related]
3. The transgenic window on lymphoid malignancy. Adams JM, Harris AW, Vaux DL, Alexander WS, Rosenbaum H, Klinken SP, Strasser A, Bath ML, McNeall J, Cory S. Princess Takamatsu Symp; 1989 Nov 22; 20():297-309. PubMed ID: 2518688 [Abstract] [Full Text] [Related]
4. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. Nuñez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. J Immunol; 1990 May 01; 144(9):3602-10. PubMed ID: 2184193 [Abstract] [Full Text] [Related]
5. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Yu D, Thomas-Tikhonenko A. Oncogene; 2002 Mar 14; 21(12):1922-7. PubMed ID: 11896625 [Abstract] [Full Text] [Related]
6. Bcl-2 confers growth and survival advantage to interleukin 7-dependent early pre-B cells which become factor independent by a multistep process in culture. Borzillo GV, Endo K, Tsujimoto Y. Oncogene; 1992 May 14; 7(5):869-76. PubMed ID: 1373874 [Abstract] [Full Text] [Related]
15. Growth of E mu-myc transgenic B-lymphoid cells in vitro and their evolution toward autonomy. Langdon WY, Harris AW, Cory S. Oncogene Res; 1988 Jun 14; 3(3):271-9. PubMed ID: 3144697 [Abstract] [Full Text] [Related]
16. ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-X(L) transgenic mice. Linden M, Kirchhof N, Kvitrud M, Van Ness B. Leuk Res; 2005 Apr 14; 29(4):435-44. PubMed ID: 15725478 [Abstract] [Full Text] [Related]
17. Interaction of abl and raf with IL-7 signaling pathway and transformation of pre-B cells from resistant mice. Hilbert DM, Theisen PW, Rudikoff EK, Bauer SR. Oncogene; 1998 Oct 22; 17(16):2125-35. PubMed ID: 9798684 [Abstract] [Full Text] [Related]
18. v-myc and v-raf act synergistically to induce B-cell tumors in pristane-primed adult BALBC mice. Kurie JM, Morse HC, Principato MA, Wax JS, Troppmair J, Rapp UR, Potter M, Mushinski JF. Oncogene; 1990 Apr 22; 5(4):577-82. PubMed ID: 2183159 [Abstract] [Full Text] [Related]
19. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Wang Y, Szekely L, Okan I, Klein G, Wiman KG. Oncogene; 1993 Dec 22; 8(12):3427-31. PubMed ID: 8247547 [Abstract] [Full Text] [Related]
20. Murine c-myc retroviruses alter the growth requirements of myeloid cell lines. Cory S, Bernard O, Bowtell D, Schrader S, Schrader JW. Oncogene Res; 1987 Jun 22; 1(1):61-76. PubMed ID: 3329710 [Abstract] [Full Text] [Related] Page: [Next] [New Search]